Literature DB >> 19116906

Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?

Paolo Picco1, Giacomo Brisca, Francesco Traverso, Anna Loy, Marco Gattorno, Alberto Martini.   

Abstract

Recurrent pericarditis occurs in association with various medical conditions, but in most cases the condition appears to be idiopathic. Although high-dose steroid treatment is often effective, it may have serious side effects. Herein we describe 3 children with recurrent pericarditis who were treated at our hospital, during flares, with the interleukin-1beta receptor antagonist anakinra, with immediate response. Pericarditis recurred when anakinra treatment was discontinued, and no further episodes occurred after it was resumed. Idiopathic recurrent pericarditis shares several features with autoinflammatory diseases, and anakinra has been efficacious in the treatment of the latter diseases. The findings in these patients suggest that idiopathic recurrent pericarditis may be a previously unrecognized autoinflammatory disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19116906     DOI: 10.1002/art.24174

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  37 in total

Review 1.  Interleukin-1 blockade for the treatment of pericarditis.

Authors:  Leo F Buckley; Michele M Viscusi; Benjamin W Van Tassell; Antonio Abbate
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2018-01-01

Review 2.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

3.  Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study.

Authors:  Luca Cantarini; Orso Maria Lucherini; Antonio Brucato; Luca Barone; Davide Cumetti; Francesca Iacoponi; Donato Rigante; Giovanni Brambilla; Silvana Penco; Maria Giuseppina Brizi; Maria Cristina Patrosso; Guido Valesini; Bruno Frediani; Mauro Galeazzi; Rolando Cimaz; Giuseppe Paolazzi; Antonio Vitale; Massimo Imazio
Journal:  Clin Res Cardiol       Date:  2012-02-05       Impact factor: 5.460

4.  A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis.

Authors:  Ian C Scott; Vijay Hajela; Philip N Hawkins; Helen J Lachmann
Journal:  J Cardiol Cases       Date:  2011-08-12

5.  Cardiac tamponade in a child with systemic-onset juvenile idiopathic arthritis: dramatic improvement after interleukin-1 blockade by anakinra.

Authors:  E Merlin; L Berthomieu; C Dauphin; J L Stéphan
Journal:  Pediatr Cardiol       Date:  2011-08       Impact factor: 1.655

Review 6.  Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term.

Authors:  Antonio Brucato; Massimo Imazio; Paul C Cremer; Yehuda Adler; Bernhard Maisch; George Lazaros; Marco Gattorno; Alida L P Caforio; Renzo Marcolongo; Giacomo Emmi; Alberto Martini; Allan L Klein
Journal:  Intern Emerg Med       Date:  2018-07-18       Impact factor: 3.397

7.  Successful treatment of idiopathic recurrent pericarditis with interleukin-1 receptor antagonist (Anakinra).

Authors:  Marisol Camacho-Lovillo; Ana Méndez-Santos
Journal:  Pediatr Cardiol       Date:  2013-03-06       Impact factor: 1.655

Review 8.  The IL-1 family: regulators of immunity.

Authors:  John E Sims; Dirk E Smith
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

Review 9.  Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.

Authors:  Giacomo Emmi; Maria Letizia Urban; Massimo Imazio; Marco Gattorno; Silvia Maestroni; Giuseppe Lopalco; Luca Cantarini; Domenico Prisco; Antonio Brucato
Journal:  Curr Cardiol Rep       Date:  2018-06-14       Impact factor: 2.931

Review 10.  Recurrent pericarditis: new and emerging therapeutic options.

Authors:  Massimo Imazio; George Lazaros; Antonio Brucato; Fiorenzo Gaita
Journal:  Nat Rev Cardiol       Date:  2015-08-11       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.